UCB has been granted a patent for sulfonamide compounds that modulate GPR17, aimed at treating or preventing central nervous system diseases, particularly demyelination disorders. The patent includes a method for administering these compounds to patients in need. GlobalData’s report on UCB gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on UCB, Human telomerase RT biomarker was a key innovation area identified from patents. UCB's grant share as of July 2024 was 49%. Grant share is based on the ratio of number of grants to total number of patents.
Gpr17 modulating sulfonamide compounds for treating demyelination disorders
The patent US12071404B2 outlines a method for treating demyelination disorders of the central nervous system, specifically targeting conditions associated with the GPR17 receptor. The treatment involves administering a therapeutically effective amount of a compound defined by a specific chemical structure, referred to as Formula I-2. The claims detail various structural modifications and derivatives of this compound, including its pharmaceutically acceptable salts, solvates, isotopes, or co-crystals. The method is particularly relevant for conditions such as multiple sclerosis (MS), neuromyelitis optica, and other demyelination disorders resulting from traumatic brain injury, hypoxia, or ischemia.
The claims further elaborate on the structural components of the compounds, specifying various substituents and their permissible variations. For instance, the compounds may include specific halogens, alkyl groups, and functional groups that enhance their therapeutic efficacy. The patent also emphasizes the oral administration of these compounds, providing a comprehensive framework for potential pharmaceutical applications in treating demyelination disorders. The detailed chemical structures and their derivatives aim to facilitate the development of targeted therapies for patients suffering from these debilitating conditions.
To know more about GlobalData’s detailed insights on UCB, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
